GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Cash And Cash Equivalents : $32.35 Mil (As of Mar. 2023)

View and export this data going back to 2022. Start your Free Trial

What is GreenLight Biosciences Holdings PBC Cash And Cash Equivalents?

GreenLight Biosciences Holdings PBC's quarterly cash and cash equivalents declined from Sep. 2022 ($98.35 Mil) to Dec. 2022 ($68.10 Mil) but then stayed the same from Dec. 2022 ($68.10 Mil) to Mar. 2023 ($32.35 Mil).

GreenLight Biosciences Holdings PBC's annual cash and cash equivalents declined from Dec. 2020 ($95.07 Mil) to Dec. 2021 ($31.45 Mil) but then increased from Dec. 2021 ($31.45 Mil) to Dec. 2022 ($68.10 Mil).

GreenLight Biosciences Holdings PBC Cash And Cash Equivalents Historical Data

The historical data trend for GreenLight Biosciences Holdings PBC's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GreenLight Biosciences Holdings PBC Cash And Cash Equivalents Chart

GreenLight Biosciences Holdings PBC Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

25.92

95.07

31.45

68.10

GreenLight Biosciences Holdings PBC Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash And Cash Equivalents	Get a 7-Day Free Trial							83.22	44.13	98.35	68.10	32.35

GreenLight Biosciences Holdings PBC Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

GreenLight Biosciences Holdings PBC (NAS:GRNA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

GreenLight Biosciences Holdings PBC Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of GreenLight Biosciences Holdings PBC's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GreenLight Biosciences Holdings PBC (NAS:GRNA) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Hartwell Avenue, Lexington, MA, USA, 02421

Website

https://www.greenlightbiosciences.com

GreenLight Biosciences Holdings PBC is a pre-commercial stage synthetic biology company with a proprietary cell-free ribonucleic acid production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company is developing RNA products for plant and life science applications to advance crop management, plant protection, animal health, vaccine development, and pandemic preparation.

Executives

Deval L Patrick	other: See Remarks	BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116
Dennis A. Clarke	other: Member of 13D group owning 10%	6 FERNWAY TERRACE, WINCHESTER MA 01890
Cummings Foundation, Inc.	other: Member of 13D group owning 10%	200 WEST CUMMINGS PARK, WOBURN MA 01801
Eric Senior Anderson	other: Member of 13D group owning 10%	25 N HILL ROAD, WESTOVER MA 01886
Mls Capital Fund Ii Lp	other: See remarks	C/O MLSC II (GP) (LABUAN) LLP, ONE MARKET ST SUITE 3525, SAN FRANCISCO CA 94105
Chelt Trading Ltd	other: Member of 13D Group	C/O FOX HORAN & CAMERINI LLP, 885 3RD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Highview Trust	other: Member of 13D Group	C/O FOX HORAN & CAMERINI LLP, 885 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Montealegre Lacayo Jaime Javier	other: Member of 13D Group	APARTADO 15-1250, ESCAZU G2
Furneaux Capital Holdco, Llc	other: Member of 13D group	1 MARINA PARK DRIVE, BOSTON MA 02210
Lewis & Clark Plant Sciences Fund I, Lp	other: Member of 13D group	120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Lewis & Clark Ventures I, Lp	other: Member of 13D group	120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Matthew Allen Walker	director, 10 percent owner	C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Martha Schlicher	director	C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Marta Ortega-valle	other: Member of 10% owner group	C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Builders Vision, Llc	10 percent owner	110 NW 2ND STREET SUITE 300, BENTONVILLE AR 72712